Biblio

Author Title Type [ Year(Desc)]
Filters: Author is Efebera, Yvonne  [Clear All Filters]
2020
Maakaron JE, Liscynesky C, Boghdadly ZEl, Huang Y, Agyeman A, Brammer J, Penza S, Efebera Y, Benson D, Rosko A, et al. Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look. Biol Blood Marrow Transplant. 2020.
2023
Nooka AK, Kaufman JL, Rodríguez C, Jakubowiak A, Efebera Y, Reeves B, Wildes T, Holstein SA, Anderson LD, Badros A, et al. A plain language summary of daratumumab plus lenalidomide/bortezomib/dexamethasone in transplant-eligible Black patients with newly diagnosed multiple myeloma in the GRIFFIN study. Future Oncol. 2023.
Chung DJ, Shah N, Wu J, Logan B, Bisharat L, Callander N, Cheloni G, Anderson K, Chodon T, Dhakal B, et al. Randomized Trial of a Personalized Dendritic Cell Vaccine after Autologous Stem Cell Transplant for Multiple Myeloma. Clin Cancer Res. 2023.
2024
Malek E, Kort J, Metheny L, Fu P, Li G, Hari P, Efebera Y, Callander NS, Qazilbash MH, Giralt S, et al. Impact of Visceral Obesity on Clinical Outcome and Quality of Life for Patients with Multiple Myeloma: A Secondary Data Analysis of STaMINA (BMT CTN 0702) Trial. Transplant Cell Ther. 2024.
Pasquini MC, Wallace PK, Logan B, Kaur M, Tario JD, Howard A, Zhang Y, Brunstein C, Efebera Y, Geller N, et al. Minimal Residual Disease Status in Multiple Myeloma 1 Year After Autologous Hematopoietic Cell Transplantation and Lenalidomide Maintenance Are Associated With Long-Term Overall Survival. J Clin Oncol. 2024:JCO2300934.